LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Rituximab as first‐line adjuvant therapy for pemphigus: Retrospective analysis of long‐term outcomes at a single center

Photo by atikahakhtar from unsplash

Supported through the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), and the NIH Medical Research Scholars Program, a… Click to show full abstract

Supported through the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), and the NIH Medical Research Scholars Program, a publicprivate partnership supported jointly by the NIH and generous contributions to the Foundation for the NIH from the Doris Duke Charitable Foundation, American Association for Dental Research, Colgate-Palmolive Company, Genentech, and alumni of student research programs and other individual supporters via contributions to the Foundation for the NIH.

Keywords: rituximab first; therapy pemphigus; research; first line; line adjuvant; adjuvant therapy

Journal Title: Journal of the American Academy of Dermatology
Year Published: 2018

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.